Neogen Chemicals Ltd Upgraded to Sell on Technical Improvement Despite Weak Financials

Technical Trend Upgrade Spurs Rating Change

The most significant factor behind the upgrade in Neogen Chemicals’ mojo grade to Sell (from Strong Sell) is the improvement in its technical trend. The technical grade has shifted from mildly bearish to mildly bullish, reflecting a more positive market sentiment around the stock. Key technical indicators present a mixed but cautiously optimistic picture. On a weekly basis, the MACD (Moving Average Convergence Divergence) is bullish, supported by bullish Bollinger Bands and a mildly bullish Dow Theory signal. However, monthly MACD and KST (Know Sure Thing) indicators remain bearish, indicating some longer-term caution.

Daily moving averages still show a mildly bearish stance, but the weekly momentum indicators have gained strength. The On-Balance Volume (OBV) indicator is bullish on a monthly scale, suggesting accumulation by investors over recent months. The Relative Strength Index (RSI) remains neutral on both weekly and monthly charts, signalling no immediate overbought or oversold conditions. This technical improvement has coincided with a sharp price rise, with the stock gaining 10.48% on the day to close at ₹1,664.50, approaching its 52-week high of ₹1,867.95.

Strong Price Performance Outpaces Sensex

Neogen Chemicals’ recent price momentum is notable when compared with the broader market. Over the past week, the stock has surged 14.83%, vastly outperforming the Sensex’s modest 0.52% gain. The one-month return stands at 24.76%, dwarfing the Sensex’s 5.34% rise. Year-to-date, the stock has delivered a remarkable 40.58% return, while the Sensex has declined by 7.87%. Even over the past year, Neogen Chemicals has managed a positive 1.72% return compared to the Sensex’s 1.36% fall. However, longer-term returns over three and five years lag the benchmark, with the stock returning 3.32% and 90.19% respectively, versus the Sensex’s 31.62% and 63.30%.

Financial Trend Remains Weak Despite Price Gains

While technicals have improved, Neogen Chemicals’ financial performance continues to disappoint. The company reported very negative results for Q3 FY25-26, with a sharp 39.95% decline in Profit Before Tax (PBT). This marks the third consecutive quarter of negative results, signalling ongoing operational challenges. The nine-month Profit After Tax (PAT) has contracted by 46.61% to ₹17.32 crores, reflecting deteriorating profitability.

Operating profit growth over the last five years has been a modest 13.43% annually, which is insufficient to offset the recent downturn. Return on Capital Employed (ROCE) for the half-year stands at a low 5.72%, while Return on Equity (ROE) averages 9.65%, both indicating weak returns on invested capital and shareholders’ funds. The company’s ability to service debt is particularly concerning, with a high Debt to EBITDA ratio of 8.54 times and an operating profit to interest coverage ratio of just 1.48 times in the latest quarter. These metrics highlight significant financial risk and limited cushion against adverse market conditions.

Valuation Remains Expensive Relative to Fundamentals

Despite the weak financials, Neogen Chemicals trades at a relatively expensive valuation. The Enterprise Value to Capital Employed ratio stands at 3.1, which is high given the company’s low ROCE of 5.9%. This suggests investors are paying a premium for the stock, possibly driven by recent technical momentum rather than fundamental strength. However, the stock is currently trading at a discount compared to its peers’ average historical valuations, which may offer some relative value.

Over the past year, the stock’s price appreciation of 1.72% contrasts with a 41.4% decline in profits, underscoring a disconnect between market pricing and earnings performance. This divergence warrants caution for investors relying solely on price trends without considering underlying business health.

Quality Assessment and Institutional Interest

Neogen Chemicals’ quality grade remains low, reflecting its poor profitability and financial risk. The company’s average ROE of 9.65% is below industry standards, and its high leverage further undermines financial stability. However, institutional investors hold a significant 26.56% stake in the company, indicating some confidence from sophisticated market participants who may have better resources to analyse the firm’s prospects. This institutional backing could provide some support to the stock amid volatility.

Balancing Technical Optimism with Fundamental Risks

In summary, the upgrade of Neogen Chemicals Ltd’s mojo grade to Sell reflects a nuanced view that technical indicators have improved sufficiently to warrant a less negative stance, moving away from Strong Sell. The weekly bullish MACD, Bollinger Bands, and Dow Theory signals, combined with strong short-term price performance, have driven this change. However, the company’s financial trend remains very negative, with declining profits, weak returns, and high leverage posing significant risks.

Valuation metrics suggest the stock is expensive relative to its earnings power, though it trades at a discount to peer historical averages. Institutional holdings provide some confidence but do not fully mitigate the fundamental concerns. Investors should carefully consider whether the recent technical momentum justifies exposure given the company’s ongoing operational and financial challenges.

For those seeking investment opportunities in the specialty chemicals sector, it may be prudent to monitor Neogen Chemicals closely for sustained improvement in financial results and leverage reduction before increasing exposure. Meanwhile, exploring alternative stocks with stronger fundamentals and comparable technical setups could offer better risk-adjusted returns.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →